Avexxin: Pioneering treatments for psoriasis and inflammatory diseases




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Avexxin: Pioneering treatments for psoriasis and inflammatory diseases
Released on: June 23, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Avexxin is a clinical-stage pharmaceutical company focused on developing a novel first-in-class small molecule platform for the treatment of inflammatory diseases.
  • Summary
  • Transcript
  • Participants
  • Company
Avexxin is a clinical-stage pharmaceutical company focused on developing a novel first-in-class small molecule platform for the treatment of inflammatory diseases. Michael Orum, president and CEO of Avexxin, discusses their lead compounds in dermatological disorders, rheumatoid arthritis and glomerulonephritis.
Avexxin is a clinical-stage pharmaceutical company focused on developing a novel first-in-class small molecule platform for the treatment of inflammatory diseases. Michael Orum, president and CEO of Avexxin, discusses their lead compounds in dermatological disorders, rheumatoid arthritis and glomerulonephritis.
Mikael Ørum joined Avexxin at its inception in 2005. Prior to this Mikael Ørum co-founded and served as general partner of Ventac Partners, an international life sciences venture catalyst company. Mikael Ørum served as President & CEO of Exiqon, a leading biotech company within the genomics field, from 1996 through 2002. In 1999, he co-founded Cureon (now Santaris Pharma), a leading antisense therapeutic company. He serves as chairman and board member of several biotech companies, including Casigen Pharma, Pharmacellion, and Neuroscience Technologies, and as scientific advisory board member of Virginia Tech Bioinformatics Institute. Furthermore, Mikael Ørum is vice chairman of Medicon Valley Alliance and Nansen Neuroscience Network. Mikael Orum has an education in banking, finance and legal from Copenhagen Business School and Copenhagen Business College.
Avexxin
Avexxin AS is a clinical stage pharmaceutical company focused on developing novel first in class small molecules for patients suffering from various inflammatory conditions. Current pipeline includes compounds against psoriasis and other dermatological disorders, rheumatoid arthritis and glomerulonephritis. Avexxin’s advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of chronic inflammatory disorders. Compounds have also been successfully tested in various cancer models. The NCE’s specifically target the group IVa cPLA2 enzyme regulating the cytokine-induced activation of the pro-inflammatory transcription factor NF-?B.